Organon & Co. (OGN) Projected to Post Earnings on Thursday

Organon & Co. (NYSE:OGN) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Organon & Co. to post earnings of $0.74 per share and revenue of $1.5152 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the company earned $1.38 earnings per share. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Price Performance

NYSE OGN opened at $8.29 on Thursday. The company has a market cap of $2.16 billion, a price-to-earnings ratio of 4.32, a PEG ratio of 1.71 and a beta of 0.58. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20. The stock’s fifty day moving average price is $7.85 and its 200 day moving average price is $8.69. Organon & Co. has a 1 year low of $6.18 and a 1 year high of $17.23.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were paid a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Thursday, November 20th. Organon & Co.’s dividend payout ratio (DPR) is presently 4.17%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC grew its holdings in Organon & Co. by 2.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after purchasing an additional 1,594 shares in the last quarter. Rafferty Asset Management LLC boosted its position in Organon & Co. by 8.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company’s stock valued at $228,000 after buying an additional 1,847 shares during the last quarter. Bank of Nova Scotia grew its stake in shares of Organon & Co. by 4.6% during the third quarter. Bank of Nova Scotia now owns 44,512 shares of the company’s stock valued at $475,000 after acquiring an additional 1,947 shares in the last quarter. Vise Technologies Inc. grew its stake in shares of Organon & Co. by 10.2% during the third quarter. Vise Technologies Inc. now owns 25,377 shares of the company’s stock valued at $271,000 after acquiring an additional 2,358 shares in the last quarter. Finally, Parallel Advisors LLC boosted its holdings in Organon & Co. by 23.2% in the third quarter. Parallel Advisors LLC now owns 16,014 shares of the company’s stock valued at $171,000 after purchasing an additional 3,020 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on OGN. Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. Zacks Research cut shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Piper Sandler downgraded Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target on the stock. in a research report on Monday, October 27th. Finally, JPMorgan Chase & Co. reduced their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $8.38.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.